Market reviews 2017

Market review on human pharmaceuticals 2017

Published on 7 February 2018

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in 2017 was up by 2% on the previous year at EUR 2,378 (2,337) million. Orion maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2017 was down by 2% compared with the previous year at EUR 294 (300) million. Orion’s market share of Finnish pharmaceuticals markets was 12% (13%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for about 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased due to generic competition.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2017 were up by 2% at EUR 537 (526) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 42% at EUR 62 (44) million in Europe.

Published on 26 October 2017

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–September 2017 was up by 2% on the previous year at EUR 1,731 (1,692) million. Orion maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2017 was at the previous year’s level at altogether EUR 219 (218) million. Orion’s market share of Finnish pharmaceuticals markets was 13% (13%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for about 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan, mainly due to growth in Stalevo, which was launched in that market in 2015.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2017 were up by 1% at EUR 536 (530) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 43% at EUR 58 (41) million in Europe.

Published on 19 July 2017

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–June 2017 was up by 1% on the previous year at EUR 1,131 (1,115) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2017 amounted to EUR 147 (143) million, up by 2% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (13%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for slightly over 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan, mainly due to growth in Stalevo, which was launched in that market in 2015.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2017 were up by 1% at EUR 530 (527) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 39% at EUR 53 (38) million in Europe.

Published on 26 April 2017

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–March 2017 was EUR 546 (538) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2017 amounted to EUR 72 (69) million, up by 4% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (13%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for slightly over 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan, mainly due to growth in Stalevo, which was launched in that market in 2015.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in December 2016 were EUR 523 (525) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 34% at EUR 48 (36) million in Europe.